Neurological Center Research

Why We Do Research | What is a Neurological Clinical Trial?
Patient's Rights and Protections
Currently Enrolling Research Trials
Ongoing Research Trials (Enrollment Closed)
Past Research Studies
General Information

Why We Do Research

For the past twenty years, the physician staff of the Fort Wayne Neurological Center (FWNC) has been actively involved in neurological clinical research. Dedication to this initiative has taken the form of physician effort to seek out and enroll patients in new studies that could result in new medications, partnerships with pharmaceutical companies, research study development organizations, local hospital research departments, and the regional medical school campus of Indiana University School of Medicine. This active involvement and leadership by FWNC physicians has resulted in the Neurological Center participating in a number of studies, including being the leading enroller of patients in several ground-breaking neurological studies. This is a unique accomplishment considering that it has customarily been academic neurology practices affiliated with major medical schools and research hospitals who have led the way in enrolling their patients in research studies. Now in Fort Wayne the Neurological Center's patients are offered the same opportunities for potential new pharmacological medications that would have been possible only at a few major urban centers, often out of the reach of any Tri-state patients and their family.

[ back to top ]

What is a Neurological Clinical Trial?

A research study, often called a clinical trial involves patients who volunteer to help doctors and researchers find better ways to prevent, treat or diagnose neurological disease. There are several types of clinical trials – some test new ways to treat the disease while others test new methods of prevention, detection or diagnosis of disease.

[ back to top ]

Patient's Rights and Protections

To protect the rights and welfare of clinical research volunteers, the Food and Drug Administration (FDA) oversees all of the medical research in the United States. When conducting clinical trials, FWNC’s most important responsibility is to protect patients through well-designed protocols, a careful informed consent process and monitoring of the safety of the clinical trial. A protocol is a detailed plan that explains what will be done in a clinical trial and why. It outlines how many patients will participate, what medical tests they will receive and how often as well as the treatment and monitoring plan.

[ back to top ]

Currently Enrolling Research Trials

Multiple Sclerosis
  • Genzyme OBS14379/IVSS: A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA® (alemtuzumab) infusions of the first treatment course

If interested in participation in this RRMS trial, please call Debi Kocks at 260-436-2416 ext 2143 or email for more information.

  • Biogen 221AD301 a multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to evaluate the efficacy and safety of Aducanumab in subjects with Early Alzheimer’s Disease. Ages 50 to 85 years old.
  • Lilly 17X-MC-LLCF: is a 52 week, multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to evaluate the efficacy and safety of LY3202626 in subjects with Mild Cognitive Impairment, Alzheimer’s Disease. Ages 55 to 85 years old.

If interested in participation in these Alzheimer’s trials, please call Debi Kocks at 260-436-2416 ext 2143 or email for more information.

Neuromyelitis Optica Trial
  • Alexion ECU NMO 301 a randomized, double-blind, placebo-controlled clinical research trial to evaluate the safety and efficacy of Eculizumab in patients with Neuromyelitis Optica. Ages 18 years and over.

If interested in participation in this NMO trial, please call Debi Kocks at 260-436-2416 ext 2143 or email for more information.

Excessive Daytime Sleepiness and Cataplexy with Narcolepsy
  • Flamel Technologies CLFT218-15001: a double-blind, randomized, placebo-controlled clinical research trial to evaluate the safety and efficacy of FT218 for the treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy.

If interested in participation in this trial, please call Debi Kocks at 260-436-2416 ext 2143 or email for more information.

Inpatient Acute Stroke Trials

FWNC is working in partnership with Parkview Research Center on the following stroke trials:

  • SWIFT PRIME Ischemic Stroke Trial
  • PRISMS Ischemic Stroke Trial
  • ATACH II Hemorrhagic Stroke Trial

Strokes are a major cause of neurological-related deaths and disabilities. There are approximately 750,000 strokes annually in the U.S. with only one approved treatment currently available. Most people who experience a stroke wait too long to seek treatment. It is critical that people recognize the signs of a stroke and receive care at once. Signs of a stroke to recognize are: sudden weakness/numbness of the face, arm or leg, especially on one side of the body; sudden confusion, trouble speaking or understanding; sudden trouble seeing in one or both eyes; sudden trouble walking, dizziness, loss of balance or coordination; sudden and severe headache with no known cause. If you or someone you know experiences any of these symptoms, seek care immediately. Every 53 seconds, someone in the U.S. has a stroke. The treatment currently approved for stroke has a window of administration of only 3 to 4½ hours. The new agents that we are studying hope to be effective at reducing the potentially devastating consequences of a stroke.

[ back to top ]

Ongoing Research Trials (Enrollment Closed)

  • Teva MS-LAQ-301E Phase 3 Extension Study to assess long-term safety, tolerability and effect on disease course of daily oral administration of laquinimod in subjects with Relapsing Remitting Multiple Sclerosis.
  • Biogen 109-MS-303 Phase 3b Dose Blind Extension Study to Determine the Long Term Safety and Efficacy of Two Doses of BG00012 in Subjects with Relapsing Remitting Multiple Sclerosis
  • Genzyme LPS13649/TOPAZ A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)

Past Research Studies Hosted at Fort Wayne Neurological Center


  • Acorda DALF PS 1016/1029 - stroke
  • Sanofi LPS13567 - multiple sclerosis
  • Biogen 101JC402 - multiple sclerosis
  • Biogen 205MS303 - multiple sclerosis
  • Genzyme CAMMS03409 - multiple sclerosis
  • Ono Pharmaceuticals ONO4641POU007 - multiple sclerosis
  • Acorda DZNS EP 1025 - seizure
  • Teva LAQ-MS-305 - multiple sclerosis
  • Abbott/EPI - epilepsy
  • ABBESTT II – stroke
  • Acetylcholine - stroke
  • ACT - multiple sclerosis
  • Allergan - headache/migraine
  • ALZA - Pain Management
  • ALZA Corp. - stroke
  • Atlantis - stroke
  • Ancrod - stroke
  • Asta-Medica - chronic, severe pain
  • Axon-stroke
  • Bayer – stroke
  • Biogen – multiple sclerosis
  • BMS - stroke
  • Cambridge/CNS - stroke
  • Cephalon - sleep disorders
  • Cephalon – seizures
  • Cerestat - traumatic brain injury
  • Daiichi - post stroke recovery with depression
  • Danone – Alzheimer’ disease
  • Eisai American/Quintiles Pacific - Alzheimer's
  • Eisai – Parkinson’s
  • Elan Pain/Clinimetrics - severe pain
  • Elan Janssen – Alzheimer’s disease
  • Eli Lily – multiple sclerosis
  • Forest - Autism
  • Genetec/nerve growth factor - diabetic peripheral neuropathy
  • Genzyme - Pompe disease
  • Glaxo-Smith-Kline – multiple sclerosis
  • Glaxo-Smith-Kline – Alzheimer’s disease
  • Glaxo-Smith-Kline – migraine
  • Glaxo Wellcome, Imitrex - migraine headaches
  • GSK - seizures
  • Immunex multiple sclerosis
  • Impax Pharma – multiple sclerosis
  • Janssen - seizures
  • J&J – seizures
  • J&J - narcolepsy
  • J & J - vascular dementia
  • J&J Stroke
  • Merck – migraines
  • Merck - stroke
  • Merz - Cervical Dystonia
  • MINT/Bayer - Alzheimer's
  • Myriad – stroke
  • Novartis – multiple sclerosis
  • Novartis –Parkinson’s disease
  • Ono Pharma - stroke
  • Ono Pharma – Alzheimer’s disease
  • Ono Pharma – Multiple sclerosis
  • Opexa – multiple sclerosis
  • Orphan - narcolepsy
  • Osmotica - MS spastcity
  • Pfizer – Alzheimer’s disease
  • Pfizer - stroke
  • Photothera - stroke
  • POINT - Ischemic Stroke
  • PRISM Registry Study
  • Roche - multiple sclerosis
  • Sanofi-Aventis CIS EFC6260
  • Sanofi - Alzheimer's disease
  • Sanofi–Aventis – multiple sclerosis
  • Sceptre - Parkinson's Disease
  • Scirex 4 AstaMedica - pain/chronic pain
  • Schwarz - Parkinson's Disease
  • Serono - Multiple Sclerosis
  • Solvay – Alzheimer’s Disease
  • Takeda Pharmaceutical - Alzheimer's Disease
  • UCB – Seizures
  • UCB – Multiple Sclerosis
[ back to top ]

General Information

Qualified participants will receive all study-related care at no charge, including physician examinations, laboratory services, imaging and study related medication.

Please feel free to call 260-436-2416 ext 2143 or 260-460-3214, or email or for more information regarding participation in currently enrolling research trials or research related questions.

At FWNC, we continually look for new research studies to offer to our patients. We are currently looking into opening additional neurological trials.

Clinical research is the backbone of the medical innovations that we all benefit from every day. Without research, we would be unable to advance medicine and improve the care we provide to patients.

[ back to top ]

What's New

Concussion Clinic for Student Athletes

Is it safe for your child to return to their sport? Expert concussion screening and treatment is available every Wednesday from 4-7 p.m.

Learn More

Welcome To Our Website!

Use these pages to learn more about our practice, our physicians, our services, and neurology. We hope you will find these pages helpful and informative as you make health care and medical decisions.